Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil and Naloxone for Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination
NCT03743805Phase 1Withdrawn
- Sponsor
- Prisma Health
- Start
- Jan 2019
- Primary completion
- Jul 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flumazenil and naloxone in sedative intoxication and opioid intoxication, sponsored by Prisma Health. Primary endpoint: Glasgow Coma Scale and Brainstem Function at 30 minutes. Planned start Jan 2019; status: withdrawn.
02
Drugs
flumazenilnaloxone
03
Conditions
sedative intoxicationopioid intoxication
Beyond the preview
Go deeper on NCT03743805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743805.